383P A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours.
Authors
El-Helali, APlummer, R
Jayson, Gordon C
Coyle, V
Drew, Y
Mescallado, Nerissa
Harris, N
Clamp, Andrew R
McCann, J
Kennedy, R
Cranston, A
Wilson, R
Affiliation
Medical Oncology, Centre for Cancer Research and Cell Biology, Belfast, UKIssue Date
2017-09
Metadata
Show full item recordCitation
383P A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx367.017Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx367.017/4108608/383PA-phase-I-doseescalation-study-of-the-novelType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx367.017